NICE recommended four in five drugs it evaluated in past decadeBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c3935 (Published 20 July 2010) Cite this as: BMJ 2010;341:c3935
- Jacqui Wise
More than four in five of the appraisal decisions on new drugs and technologies made by the UK National Institute for Health and Clinical Excellence (NICE) are positive, new data show.
Of the 367 decisions made by NICE between 1 March 2000 and 30 June 2010, 67% were categorised as recommended and 16% as “optimised,” which means the treatment is recommended in certain circumstances. In 6% of cases the treatment was categorised for use only in research, and in 11% of cases the treatment was not recommended.
Andrew Dillon, chief executive of NICE, told a media briefing that although the body tends to attract adverse publicity when it rules against a …
Log in using your username and password
Log in through your institution
Sign up for a free trial